UBE (4208) Q4 2026 earnings summary

Executive summary

• FY2025 saw a 5.0% decrease in net sales to ¥462.3B, but operating profit rose 5.0% to ¥18.9B and profit attributable to owners of parent rebounded to ¥23.9B from a ¥4.8B loss year-over-year.

• Ordinary profit surged 67.7% to ¥37.5B, and comprehensive income reached ¥54.4B, reversing a prior year loss.

• Segment reclassification expanded reporting from four to six segments, with High Performance Urethane and Pharmaceutical now independent segments.

• FY2026 forecasts anticipate a 4.9% increase in net sales to ¥485.0B and a 24.1% rise in operating profit to ¥23.5B.

• Profit attributable to owners of parent projected at ¥24.5B, up 2.6% year-over-year.

Financial highlights

• EBITDA increased 2.1% to ¥46.4B in FY2025.

• Net income per share improved from a ¥49.60 loss to ¥245.76.

• Total assets rose by ¥80.1B to ¥946.3B, with interest-bearing debt up ¥27.6B to ¥358.2B.

• Shareholders' equity ratio improved to 46.2% for FY2025.

• Cash flows from operating activities were ¥59.98B, up from ¥35.84B year-over-year.

Outlook and guidance

• FY2026 guidance projects net sales of ¥485.0B, operating profit of ¥23.5B, and profit attributable to owners of parent of ¥24.5B.

• Dividend policy under review; FY2026 dividend forecast to be announced May 20, 2026.

• Capital investment planned at ¥85.0B and R&D expenses at ¥13.0B for FY2026.